130 related articles for article (PubMed ID: 38204397)
1. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation.
Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Urosevic A; Lefebvre P; Pilon D; George DJ
J Med Econ; 2024; 27(1):201-214. PubMed ID: 38204397
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States.
Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George D
J Med Econ; 2024; 27(1):381-391. PubMed ID: 38420699
[TBL] [Abstract][Full Text] [Related]
3. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
[TBL] [Abstract][Full Text] [Related]
5. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
6. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases.
Wen L; Yao J; Valderrama A
J Manag Care Spec Pharm; 2019 Mar; 25(3-b Suppl):S1-S11. PubMed ID: 30827188
[TBL] [Abstract][Full Text] [Related]
8. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
[TBL] [Abstract][Full Text] [Related]
9. The cost impact of disease progression to metastatic castration-sensitive prostate cancer.
Trinh QD; Chaves LP; Feng Q; Zhu J; Sandin R; Abbott T
J Manag Care Spec Pharm; 2022 May; 28(5):544-554. PubMed ID: 35471070
[No Abstract] [Full Text] [Related]
10. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
Armstrong A; Bui C; Fitch K; Sawhney TG; Brown B; Flanders S; Balk M; Deangelis J; Chambers J
Curr Med Res Opin; 2017 Jun; 33(6):1133-1139. PubMed ID: 28318331
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data.
Freedland SJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Ryan CJ
Curr Med Res Opin; 2021 Apr; 37(4):609-622. PubMed ID: 33476184
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.
Freedland SJ; Davis M; Epstein AJ; Arondekar B; Ivanova JI
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):327-333. PubMed ID: 37783836
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
[TBL] [Abstract][Full Text] [Related]
14. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.
Dragomir A; Dinea D; Vanhuyse M; Cury FL; Aprikian AG
BMC Health Serv Res; 2014 Jun; 14():252. PubMed ID: 24927758
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
Mehra M; Wu Y; Dhawan R
J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
[TBL] [Abstract][Full Text] [Related]
16. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
Flaig TW; Potluri RC; Ng Y; Todd MB; Mehra M
Cancer Med; 2016 Feb; 5(2):182-91. PubMed ID: 26710718
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data.
Liu J; Near A; Chiarappa JA; Wada K; Tse J; Burudpakdee C; Behl A; Ranganath R; Antonarakis ES
J Med Econ; 2019 Oct; 22(10):1080-1087. PubMed ID: 31352849
[No Abstract] [Full Text] [Related]
18. Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings.
Qian Z; Wang Y; Tang Z; Ren D; Wang Z; Chen W; Li Z
J Med Econ; 2019 Aug; 22(8):728-735. PubMed ID: 30913930
[No Abstract] [Full Text] [Related]
19. Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.
Freedland SJ; Hong A; El-Chaar N; Murty S; Ramaswamy K; Coutinho AD; Nimke D; Morgans AK
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):523-530. PubMed ID: 36517634
[TBL] [Abstract][Full Text] [Related]
20. Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
Ryan CJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Freedland SJ
J Urol; 2021 Dec; 206(6):1420-1429. PubMed ID: 34293915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]